Verizon to cut 15,000 jobs amid growing competition pressures - WSJ
Investing.com - Oppenheimer has reiterated an Outperform rating on Boston Scientific (NYSE:BSX), a $144.66 billion medical device giant, with a price target of $125.00 following the company’s 2025 Investor Conference held Tuesday. According to InvestingPro data, the stock currently appears overvalued based on its Fair Value analysis, though it maintains strong financial health with an overall score of "GREAT."
Boston Scientific reaffirmed its fiscal year 2025 organic sales growth forecast of 14-15% during the conference, while maintaining its long-term growth projection of at least 10%. The company’s confidence appears well-founded, with recent revenue growth reaching 21.44% and strong profitability metrics. The company also outlined goals for adjusted operating margin expansion of approximately 50 basis points per year and double-digit adjusted EPS growth.
The medical device manufacturer highlighted diverse portfolio opportunities, with pulse field ablation (PFA) and left atrial appendage closure (LAAC) performance identified as critical components for achieving growth targets. Boston Scientific also positioned heart failure treatments and intravascular lithotripsy (IVL) as future growth drivers.
The company detailed plans for a steady pipeline of new product introductions and clinical trials to support both new markets and indications. Boston Scientific is also laying groundwork to increase its international sales from approximately 35% currently to 40-45% of total business.
Oppenheimer noted that Boston Scientific’s financial targets appear reasonable, though the analyst firm expressed uncertainty about the potential impact of tariffs on the company’s financial outlook. With a strong buy consensus among analysts and 12 additional key insights available on InvestingPro, investors can access comprehensive analysis including the company’s detailed Pro Research Report, which transforms complex Wall Street data into actionable intelligence.
In other recent news, Boston Scientific has been the focus of several analyst updates following its investor presentations. Truist Securities raised its price target for the company to $129, maintaining a Buy rating, after Boston Scientific outlined its long-term growth plan for 2026-2028, which includes projections of over 10% organic revenue growth and double-digit annual EPS growth. Similarly, Canaccord Genuity increased its price target to $132, also maintaining a Buy rating, highlighting the company’s strategy to achieve a compound annual growth rate of over 10% in organic sales and operating margin expansion. BTIG echoed this sentiment by raising its price target to $132, citing the same financial targets and emphasizing the company’s potential for significant free cash flow conversion.
RBC Capital reiterated its Outperform rating with a $125 price target, expressing continued confidence ahead of Boston Scientific’s 2025 Investor Conference. Piper Sandler also maintained its Overweight rating and $115 price target, showing optimism about the CHAMPION-AF study, which could enhance the company’s Watchman franchise. These developments reflect a positive outlook from analysts based on Boston Scientific’s strategic plans and growth projections for the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.